Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2016; 6(9):1467-1476. doi:10.7150/thno.16003 This issue Cite

Research Paper

In Vivo Targeting of Metabolically Labeled Cancers with Ultra-Small Silica Nanoconjugates

Hua Wang1, Li Tang1, Yang Liu1, Iwona Teresa Dobrucki2, Lawrence W. Dobrucki3, Lichen Yin4✉, Jianjun Cheng1✉

1. Department of Materials Science and Engineering, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA.
2. Molecular Imaging Laboratory, Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA.
3. Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA.
4. Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Institute of Functional Nano & Soft Materials (FUNSOM), Collaborative Innovation Center of Suzhou Nano Science and Technology, Soochow University, Suzhou 215123, Jiangsu, China.

✉ Corresponding authors: jianjuncedu, lcyinedu.cn.

Citation:
Wang H, Tang L, Liu Y, Dobrucki IT, Dobrucki LW, Yin L, Cheng J. In Vivo Targeting of Metabolically Labeled Cancers with Ultra-Small Silica Nanoconjugates. Theranostics 2016; 6(9):1467-1476. doi:10.7150/thno.16003. https://www.thno.org/v06p1467.htm
Other styles

File import instruction

Abstract

Unnatural sugar-mediated metabolic labeling of cancer cells, coupled with efficient Click chemistry, has shown great potential for in vivo imaging and cancer targeting. Thus far, chemical labeling of cancer cells has been limited to the small-sized azido groups, with the large-sized and highly hydrophobic dibenzocyclooctyne (DBCO) being correspondingly used as the targeting ligand. However, surface modification of nanomedicines with DBCO groups often suffers from low ligand density, difficult functionalization, and impaired physiochemical properties. Here we report the development of DBCO-bearing unnatural sugars that could directly label LS174T colon cancer cells with DBCO groups and subsequently mediate cancer-targeted delivery of azido-modified silica nanoconjugates with easy functionalization and high azido density in vitro and in vivo. This study, for the first time, demonstrates the feasibility of metabolic labeling of cancer cells with large-sized DBCO groups for subsequent, efficient targeting of azido-modified nanomedicines.

Keywords: Click chemistry, cancer targeting, nanomedicine, silica nanoconjugate, multi-modal imaging.

Citation styles

APA
Wang, H., Tang, L., Liu, Y., Dobrucki, I.T., Dobrucki, L.W., Yin, L., Cheng, J. (2016). In Vivo Targeting of Metabolically Labeled Cancers with Ultra-Small Silica Nanoconjugates. Theranostics, 6(9), 1467-1476. https://doi.org/10.7150/thno.16003.

ACS
Wang, H.; Tang, L.; Liu, Y.; Dobrucki, I.T.; Dobrucki, L.W.; Yin, L.; Cheng, J. In Vivo Targeting of Metabolically Labeled Cancers with Ultra-Small Silica Nanoconjugates. Theranostics 2016, 6 (9), 1467-1476. DOI: 10.7150/thno.16003.

NLM
Wang H, Tang L, Liu Y, Dobrucki IT, Dobrucki LW, Yin L, Cheng J. In Vivo Targeting of Metabolically Labeled Cancers with Ultra-Small Silica Nanoconjugates. Theranostics 2016; 6(9):1467-1476. doi:10.7150/thno.16003. https://www.thno.org/v06p1467.htm

CSE
Wang H, Tang L, Liu Y, Dobrucki IT, Dobrucki LW, Yin L, Cheng J. 2016. In Vivo Targeting of Metabolically Labeled Cancers with Ultra-Small Silica Nanoconjugates. Theranostics. 6(9):1467-1476.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use